Healthy Clinical Trial
Official title:
Impact of Single Exercise Session Conducted Prior to Phenylketonuria (PKU) Type Meal on Appetite Hormones, Metabolic Rate, Fat Oxidation and Energy Intake
| NCT number | NCT04302285 |
| Other study ID # | 200170151 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | June 3, 2018 |
| Est. completion date | July 5, 2019 |
| Verified date | March 2020 |
| Source | University of Glasgow |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The study applied a randomized, crossover design with preliminary (screening) session and two sequenced experimental trials. Trials were marked as Control trial and Exercise trial. Participants were asked to either resting (Control trial) or exercising (Exercise trial) for one hour. In the two trials, appetite questionnaires were obtained, blood samples were collected, and metabolic rates were measured every 30 minutes. Participants in both trials were presented to a standard isocaloric PKU type meal at 120 min. After the completion of the last measurement, the participants were presented with an ad libitum buffet test meal at 300 min. Participants required to record their EI for the remainder of the experimental day using a self-recorded food diary. Two days prior the experimental trials participants refrained from exercise and alcohol intake. All data collection took place in the metabolic research unit at New Lister Building, Glasgow Royal Infirmary.
| Status | Completed |
| Enrollment | 16 |
| Est. completion date | July 5, 2019 |
| Est. primary completion date | June 4, 2019 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Male |
| Age group | 22 Years to 35 Years |
| Eligibility |
Inclusion Criteria: - Healthy men with - Body mass index (BMI) =29 kg/m2 - Aged 22-35 years - Stable body weight for one month prior to study enrolment, and were - Not taking any medication, nutritional supplement or being on a special diet. Exclusion Criteria: - Smokers - Chronic illness - Eating disorder - History of gastrointestinal operations which could interfere with the results of the study |
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | Univesrity of Glasgow | Glasgow |
| Lead Sponsor | Collaborator |
|---|---|
| University of Glasgow |
United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Peptide YY (PYY) | Changes in plasma concentration of fasting and postprandial PYY were measured during the Exercise and Control trials. | 300 minutes through study completion, an average of 12 days | |
| Primary | Glucagon-like peptide-1 (GLP-1) | Changes in plasma concentration of fasting and postprandial GLP-1 were measured during the Exercise and Control trials. | 300 minutes through study completion, an average of 12 days | |
| Secondary | Subjective appetite score | Appetite scores during Exercise and Control trials were assessed using a 100-mm Visual Analog Scale, with 0 mm meaning one and 100 mm another extreme of hunger, desire to eat, fullness, prospective food consumption, and satiety. | 300 minutes through study completion, an average of 12 days | |
| Secondary | Dietary intake | Energy and macronutrient intake during Exercise and Control trials was analysed using WinDiets software based on food composition tables. | 24 hours through study completion, an average of 12 days | |
| Secondary | Diet induced thermogenesis | Metabolic rate measured during Exercise and Control trials by means of indirect calorimetry | 300 minutes through study completion, an average of 12 days | |
| Secondary | Growth differentiation factor 15 (GDF-15) | Changes in plasma concentration of fasting and postprandial GDF-15 were measured during the Exercise and Control trials. | 300 minutes through study completion, an average of 12 days | |
| Secondary | Fat oxidation | Rate of fat oxidation during Exercise and Control trials was measured by means of indirect calorimetry | 300 minutes through study completion, an average of 12 days |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |